Company / Accounts Receivable
ALNYLAM PHARMACEUTICALS, INC. Accounts Receivable History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$777.6M
FY2025
5-year range
$198.6M / $777.6M
FY2021-FY2025
Trend
+91.8%
vs FY2024
Sector context
#21 of 115
Health Care
What the data says
ALNYLAM PHARMACEUTICALS, INC.'s accounts receivable of $778M is higher than 82% of companies in the Health Care sector (FY2025). Accounts Receivable has increased for 7 consecutive years, from $19M in FY2018 to $778M in FY2025.
Based on SEC 10-K filings.
$778M in FY2025 with a 5-year CAGR of +50.0%. Top quartile in the Health Care sector.
Improved from $328M to $778M over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +48.4%
- 5-Year CAGR
- +50.0%
- 10-Year CAGR
- -
Sector benchmark
-30.4% below sector average
Key checks
Key Insights
- ALNYLAM PHARMACEUTICALS, INC.'s accounts receivable has grown for 7 consecutive years.
- 5-year CAGR of +50.0%, indicating consistent growth.
- In FY2025, accounts receivable increased 91.8% year-over-year.
- Ranks #21 out of 115 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.37 (distress zone, below 1.8 threshold)
- Negative profit margin: -12.4%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $777.6M | +91.8% |
| FY2024 | $405.3M | +23.6% |
| FY2023 | $327.8M | +37.7% |
| FY2022 | $238.0M | +19.8% |
| FY2021 | $198.6M | +93.9% |
| FY2020 | $102.4M | +138.1% |
| FY2019 | $43.0M | +129.3% |
| FY2018 | $18.8M | -44.8% |
| FY2017 | $34.0M | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026